关注
Lisa Bero
Lisa Bero
在 sydney.edu.au 的电子邮件经过验证
标题
引用次数
年份
‘Lines in the sand’: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders
L Parker, Q Grundy, A Fabbri, B Mintzes, L Bero
BMJ open 11 (2), e045140, 2021
62021
'Somebody Might Actually Make Up Data': An Empirical Qualitative Study on How to Screen for Fake Research
L Parker, S Boughton, R Lawrence, L Bero
Available at SSRN 4071671, 2022
22022
'Spin'in published biomedical literature: A methodological systematic review
L Bero, K Chiu, Q Grundy
Public Library of Science, 2017
2017
‘Spin’in published biomedical literature: a methodological systematic review
K Chiu, Q Grundy, L Bero
PLoS Biology 15 (9), e2002173, 2017
2422017
" Educational" advertisements--I haven't seen one yet!
LA Bero
The Western Journal of Medicine 174 (6), 395, 2001
12001
" It’s Not Smooth Sailing": Bridging the Gap Between Methods and Content Expertise in Public Health Guideline Development
N Chartres, Q Grundy, LM Parker, LA Bero
International Journal of Health Policy and Management 9 (8), 335, 2020
32020
" The tobacco products research trust 1982-1996"-In Reply
LA Bero
TOBACCO CONTROL 7 (2), 193-193, 1998
1998
“A delicate diplomatic situation”: tobacco industry efforts to gain control of the Framingham Study
JK Cataldo, LA Bero, RE Malone
Journal of clinical epidemiology 63 (8), 841-853, 2010
172010
“Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study
L Parker, A Fabbri, Q Grundy, B Mintzes, L Bero
bmj 367, 2019
222019
“Developing good taste in evidence”: facilitators of and hindrances to evidence‐informed health policymaking in state government
CJ Jewell, LA Bero
The Milbank Quarterly 86 (2), 177-208, 2008
2482008
“Experimental” institutional models for corporate funding of academic research: Unknown effects on the research enterprise
L Bero
Journal of clinical epidemiology 61 (7), 629-633, 2008
112008
“Never waste a good crisis”: Opportunities and constraints from the COVID-19 pandemic on pharmacists’ scope of practice
K Chiu, AM Thow, L Bero
Research in Social and Administrative Pharmacy 18 (9), 3638-3648, 2022
72022
“The lesser of two evils”: a framework analysis of consumers' perspectives on opioid deprescribing and the development of opioid deprescribing guidelines
AV Langford, D Gnjidic, CWC Lin, L Bero, F Blyth, J Penm, CR Schneider
Pain 162 (11), 2686-2692, 2021
172021
“There are ways… drug companies will get into DTC decisions”: How Australian drug and therapeutics committees address pharmaceutical industry influence
L Parker, A Bennett, B Mintzes, Q Grundy, A Fabbri, EA Karanges, L Bero
British Journal of Clinical Pharmacology 87 (5), 2341-2353, 2021
82021
[O31] Reporting bias in clinical trials
K Rising, K Lee, L Bero
Cochrane Colloquium Abstracts Journal, 2007
2007
[P121] Peer review and editorial decision-making at major biomedical journals
K Lee, E Boyd, J Lightwood, L Bero
Cochrane Colloquium Abstracts Journal, 2006
2006
075 The Use of GRADE Methods in the World Health Organization (Who) Public Health Guidelines (PHG): Distribution of Strength of Recommendations and Confidence in Estimates of …
P Elias, S Norris, J Brito, R Stoltzfus, L Bero, B Djulbegovic, I Neumann, ...
BMJ Quality & Safety 22 (Suppl 1), A36-A36, 2013
2013
19 Pharmaceutical industry payments to thought leaders in cardiovascular disease and diabetes
E Karanges, N Ting, L Parker, A Fabbri, L Bero
BMJ Evidence-Based Medicine 24 (Suppl 2), A16-A16, 2019
2019
59 Perspectives of deprescribing experts on opioid overtreatment in australia: a focus group study
C Schneider, A Langford, C Lin, J Penm, F Blyth, L Bero, D Gnjidic
BMJ Evidence-Based Medicine 24 (Suppl 2), A35-A35, 2019
2019
813 Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better Maarten Boers 815 A delicate diplomatic situation Richard B. Campbell 818 The recession …
DM Cook, A Stang, C Poole, R Bender, D Westreich, J Lessler, MJ Funk, ...
系统目前无法执行此操作,请稍后再试。
文章 1–20